Industry News

• Medtronic finds TAVI with CoreValve® system cost effective for severe aortic stenosis  Medtronic reported results of a cost-effectiveness model comparing transcatheter aortic valve implantation with CoreValve System to medical management. The analysis compared Medtronic CoreValve ADVANCE study to the PARTNER B study and found that the CoreValve System was cost-effective.
  May 21, 2013  
• Top-line data demonstrate primary endpoint achieved in final pivotal phase 3 study  AcelRx announced top-line data demonstrating that in a placebo-controlled Phase 3 study of its investigational sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System (NanoTab System), the primary efficacy endpoint was achieved.
  May 21, 2013  
• Acorda announces publication of new data on impact of mobility impairment due to MS  Acorda announced new research findings that show a loss of mobility due to MS has a negative impact on work productivity and patient-reported perceptions of health. The paper, published in PLoS ONE, estimated total costs of this lost productivity exceed $30,000 per person with MS, per year.
  May 21, 2013  
• Sanofi and Regeneron announce publication of positive phase 2a results of dupilumab  Sanofi and Regeneron announced the New England Journal of Medicine published the positive Phase 2a study results of dupilumab in patients with moderate-to-severe allergic asthma. Dupilumab is an investigational monoclonal antibody targeting the alpha subunit of the interleukin 4 receptor.
  May 21, 2013  
• St. Jude Medical announces start of landmark EnligHTNment clinical study  St. Jude Medical announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and medication offers additional health benefits beyond lowering blood pressure in patients with uncontrolled hypertension.
  May 21, 2013  
• Drugs found to both prevent and treat Alzheimer’s Disease in mice  Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer’s Disease in mice. The drugs, known as "TSPO ligands," are currently used for certain types of neuroimaging. The team’s findings were published online by The Journal of Neuroscience.
  May 21, 2013  
• Medtronic announces CE Mark and launch for CapSureFix Novus(TM) 5076 MRI lead  Medtronic announced CE Mark and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S.
  May 21, 2013  
• Boston Scientific long term data demonstrate bronchial thermoplasty treatment benefits  Five-year data from the Asthma Intervention Research 2 clinical trial demonstrated the Boston Scientific Alair® Bronchial Thermoplasty System continues to show therapy benefits in adult patients with severe uncontrolled asthma.
  May 21, 2013  
• Nation equipped to grow serious amounts of pond scum for fuel  A new analysis shows that the nation's land and water resources could likely support the growth of enough algae to produce up to 25 billion gallons of algae-based fuel a year in the U.S., one-twelfth of the country's yearly needs.
  May 21, 2013  Tom Rickey
• Abbott announces CE Mark for world's longest coronary drug eluting stent  Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease.
  May 21, 2013  

   (next 10 articles)